Treatment of progressive ischemic stroke with low‑dose eptifibatide: A retrospective case‑control study

Luo,Long; Lin,Jinsheng; Deng,Ye; Li,Zhigang; Yuan,Ying; Zhang,Wen

doi:10.3892/etm.2022.11721

Treatment of progressive ischemic stroke with low‑dose eptifibatide: A retrospective case‑control study

Authors:
- Long Luo
- Jinsheng Lin
- Ye Deng
- Zhigang Li
- Ying Yuan
- Wen Zhang
View Affiliations

Affiliations: Department of Neurology, Xiangtan Central Hospital, Xiangtan, Hunan 411100, P.R. China
Published online on: November 22, 2022 https://doi.org/10.3892/etm.2022.11721
Article Number: 22
Copyright: © Luo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Progressive ischemic stroke (PIS) is a therapeutic challenge in clinical practice. The present retrospective study aimed to investigate the safety and effectiveness of eptifibatide in the treatment of PIS. The present study enrolled patients with PIS admitted to Xiangtan Central Hospital (Xiangtan, China) between March 2020 and March 2021 with National Institutes of Health Stroke Scale (NIHSS) progression scores of ≥2 points during the initial 72 h. Patients were then divided into two groups according to their different anti‑platelet treatment regimens. The control group was administered anti‑platelet aggregation with aspirin 100 mg/day, or aspirin 100 mg/day in combination with clopidogrel 75 mg/day, whilst eptifibatide was administered in the eptifibatide group in addition to the treatment regimen used in the control group. Changes in NIHSS scores at the time of progression and 7 days after treatment (∆NIHSS) were used to assess early neurological recovery, and there were no significant differences in ∆NIHSS and adverse reactions between the groups (P>0.05). Subgroup analysis was subsequently performed according to the type of blood vessel that was involved [large artery atherosclerosis (LAA) or small artery occlusion (SAO)]. For the SAO subgroup, the ∆NIHSS in the eptifibatide group was significantly superior to that of the control group (P=0.008), while for the LAA subgroup, there were no significant differences in ∆NIHSS between groups (P=0.334). The present retrospective study found that patients with PIS tolerated eptifibatide treatment well. Eptifibatide exerted different effects on patients with acute PIS involving different types of blood vessels compared with oral antiplatelet drugs. In addition, application of eptifibatide may lead to faster and earlier recovery in patients with SAO, but not in those with LAA. Low‑dose eptifibatide is a safe and effective treatment option for patients with PIS caused by SAO.

View Figures

View References

1	Eriksson M, Stecksén A, Glader EL, Norrving B, Appelros P, Hulter Åsberg K, Stegmayr B, Terént A and Asplund K: Riks-Stroke Collaboration. Discarding heparins as treatment for progressive stroke in Sweden 2001 to 2008. Stroke. 41:2552–2558. 2010.PubMed/NCBI View Article : Google Scholar
2	Birschel P, Ellul J and Barer D: Progressing stroke: Towards an internationally agreed definition. Cerebrovasc Dis. 17:242–252. 2004.PubMed/NCBI View Article : Google Scholar
3	Helleberg BH, Ellekjaer H and Indredavik B: Outcomes after early neurological deterioration and transitory deterioration in acute ischemic stroke patients. Cerebrovasc Dis. 42:378–386. 2016.PubMed/NCBI View Article : Google Scholar
4	Weimar C, Mieck T, Buchthal J, Ehrenfeld CE, Schmid E and Diener HC: German Stroke Study Collaboration. Neurologic worsening during the acute phase of ischemic stroke. Arch Neurol. 62:393–397. 2005.PubMed/NCBI View Article : Google Scholar
5	Kwan J and Hand P: Early neurological deterioration in acute stroke: Clinical characteristics and impact on outcome. QJM. 99:625–633. 2006.PubMed/NCBI View Article : Google Scholar
6	Seners P and Baron JC: Revisiting ‹progressive stroke›: Incidence, predictors, pathophysiology, and management of unexplained early neurological deterioration following acute ischemic stroke. J Neurol. 265:216–225. 2018.PubMed/NCBI View Article : Google Scholar
7	Caplan LR: Treatment of ‘progressive’ stroke. Stroke. 22:694–695. 1991.PubMed/NCBI View Article : Google Scholar
8	Schwarz M, Meade G, Stoll P, Ylanne J, Bassler N, Chen YC, Hagemeyer CE, Ahrens I, Moran N, Kenny D, et al: Conformation-specific blockade of the integrin GPIIb/IIIa: A novel antiplatelet strategy that selectively targets activated platelets. Circ Res. 99:25–33. 2006.PubMed/NCBI View Article : Google Scholar
9	Casserly IP and Topol EJ: Glycoprotein IIb/IIIa antagonists-from bench to practice. Cell Mol Life Sci. 59:478–500. 2002.PubMed/NCBI View Article : Google Scholar
10	Adams HP Jr, Effron MB, Torner J, Dávalos A, Frayne J, Teal P, Leclerc J, Oemar B, Padgett L, Barnathan ES, et al: Emergency administration of abciximab for treatment of patients with acute ischemic stroke: Results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke. 39:87–99. 2008.PubMed/NCBI View Article : Google Scholar
11	Puri A, Bansal A, Narain VS, Sethi R, Dwivedi SK, Puri VK and Saran RK: Comparative assessment of platelet GpIIb/IIIa receptor occupancy ratio with Eptifibatide/Tirofiban in patients presenting with ACS and undergoing PCI. Indian Heart J. 65:152–157. 2013.PubMed/NCBI View Article : Google Scholar
12	Zhou X, Wu X, Sun H and Li J: Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta-analysis. J Evid Based Med. 10:136–144. 2017.PubMed/NCBI View Article : Google Scholar
13	Yang M, Huo X, Miao Z and Wang Y: Platelet glycoprotein IIb/IIIa receptor inhibitor tirofiban in acute ischemic stroke. Drugs. 79:515–529. 2019.PubMed/NCBI View Article : Google Scholar
14	Martin-Schild S, Shaltoni H, Abraham AT, Barreto AD, Hallevi H, Gonzales NR, Grotta JC and Savitz SI: Safety of eptifibatide for subcortical stroke progression. Cerebrovasc Dis. 28:595–600. 2009.PubMed/NCBI View Article : Google Scholar
15	Philipps J, Thomalla G, Glahn J, Schwarze M and Rother J: Treatment of progressive stroke with tirofiban-experience in 35 patients. Cerebrovasc Dis. 28:435–438. 2009.PubMed/NCBI View Article : Google Scholar
16	Peng B and Wu B: Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018. Chin J Neurol. 51:666–682. 2018.
17	Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X, Cui L, et al: Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 369:11–19. 2013.PubMed/NCBI View Article : Google Scholar
18	Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella D, Turan TN, Janis LS, Montgomery J, Nizam A, Lane BF, Lutsep HL, et al: Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): The final results of a randomised trial. Lancet. 383:333–341. 2014.PubMed/NCBI View Article : Google Scholar
19	Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF, et al: Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 365:993–1003. 2011.PubMed/NCBI View Article : Google Scholar
20	Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL and Marsh EE III: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke. 24:35–41. 1993.PubMed/NCBI View Article : Google Scholar
21	Kirmani JF, Korya D, Choi G, Brar J, Chahal H, Hussain M, Mehta S, Panezai S and Moussavi M: Abstract T P3: Safety of eptifibatide after full dose IV tPA and endovascular treatment for ischemic stroke. Stroke. 46 (suppl_1)(ATP3)2015.
22	Ma G, Sun X, Cheng H, Burgin WS, Luo W, Jia W, Liu Y, He W, Geng X, Zhu L, et al: Combined approach to eptifibatide and thrombectomy in acute ischemic stroke because of large vessel occlusion: A matched-control analysis. Stroke. 53:1580–1588. 2022.PubMed/NCBI View Article : Google Scholar
23	Kim SK, Song P, Hong JM, Pak CY, Chung CS, Lee KH and Kim GM: Prediction of progressive motor deficits in patients with deep subcortical infarction. Cerebrovasc Dis. 25:297–303. 2008.PubMed/NCBI View Article : Google Scholar
24	Steinke W and Ley SC: Lacunar stroke is the major cause of progressive motor deficits. Stroke. 33:1510–1516. 2002.PubMed/NCBI View Article : Google Scholar
25	Donnan GA, O'Malley HM, Quang L, Hurley S and Bladin PF: The capsular warning syndrome: Pathogenesis and clinical features. Neurology. 43:957–962. 1993.PubMed/NCBI View Article : Google Scholar
26	Foschi M, Pavolucci L, Rondelli F, Barone V, Rinaldi R, Spinardi L, Favaretto E, Rucci P, Giostra F, Cosmi B, et al: Capsular warning syndrome: Features, risk profile, and prognosis in a large prospective TIA cohort. Cerebrovasc Dis: Sep 9, 2022 (Epub ahead of print).
27	Li W, Wu Y, Li XS, Liu CC, Huang SH, Liang CR, Wang H, Zhang LL, Xu ZQ, Wang YJ and Zhang M: Intravenous tirofiban therapy for patients with capsular warning syndrome. Stroke Vasc Neurol. 4:22–27. 2019.PubMed/NCBI View Article : Google Scholar
28	Lin L, Li W, Liu CC, Wu Y, Huang SH, Li XS, Liang CR, Wang H, Zhang LL, Xu ZQ, et al: Safety and preliminary efficacy of intravenous tirofiban in acute ischemic stroke patient without arterial occlusion on neurovascular imaging studies. J Neurol Sci. 383:175–179. 2017.PubMed/NCBI View Article : Google Scholar